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A 30-year-old homosexual man presented with wMespread Burkitt’s 
lymphoma. On the basis of immunologic and viral studies, he was 
suspected of having the acquired immune deficiency syndr6me. 
Following chetiotherapy that incllided intrathecal cytoslne ara- 
binoside and methotrexate, brain stem edema, paraplegia, and an 
elevated cembmspinal HUM level of myelln basic protein developed. 
A&p&y revealed vacuolar demyelinatlon of spinal cord, braiir stem, 
and cerebellum. The pathologic findings were similar td those re- 
ported to occur in myelopathy associated with intrathecal chemo- 
therapy, but far more extensive. The contributidn df the suspected 
acquired immune deficiency syndrome is unknown. 
Although a variety of toxicities have been reported after intrathecal 
chemotherapy, in many patients it may be difiicult to determine the 
relative contributions of the therapy and the underlying malighancy. 
Recently, there have been reports 6f the development of undifferen- 
tiated lymphoma in patients with the acquired immune deficiency 
syndrome (AIDS) [ 11. Since involvement of the nervous system by 
the lymphoma is common in such p&tier&, intrathecal chemotherapy 
is a vital component of treatment. Yet these patients are highly sus- 
ceptible to a variety of infections, many involving the nervous system, 
and neurolqgic syndromes of unknown origin have also been de- 
scribed. Patients with this syndrdme may therefore be at particular 
risk of neurologic compiications of therapy. 
We describe herein a 30-year-old homosexual man with extensive 
Burkitt’s lymphoma and suspected AIDS in whom a myelopathy de- 
veloped after chemotherapy that included intrathecal treatment. The 
myelopathy, which extended into the brain stem and resulted in in- 
creased intracranial pressure, was mor6 severe than cases previousiy 
reported and led to the patient’s death. None of the neurologic disor- 
ders usually described in AIDS could account for the noninfiammatory 
vacuolar demyelination that involved spinal cord, brain stem, and 
cerebellum. However, an underlying abnormal imtiune system may 
have contributed to the extensive nature of the presuinptive neurotoxic 
ieaction. 
CASE REPORi 
A 30-year&Id white homosexual man was admitted with progressive stupor, 
fever, weakness, and disconjugate gaze. He had no significant past inedical 
history, but fcur mcnths earlier he had noted the onset of marked fatigue and 
an eight-pound weight loss. One month prior to admisQon, biopsy of an en- 
larged right cervical node revealed reactive hyperplasia. At that time, his 
hemoglobin level was 11.9 g/di, lactic dehydrogenase level 420 IWliter, and 
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erythrocyte sedimentation rate 88 mm per hour. One week 
prior to admission, he was noted to have mild lymphade- 
nopathy and oral candidiasis. His creatine phosphokinase 
level was 2,900 IWliter and lactic dehydrogenase level 3,060 
IV/liter. Stupor and gaze paresis then developed which led 
to his referral. 
On. admission, he was cachectic and stuporous but re- 
sponsive to questions. His temperature was 39’C, and res- 
piratory rate 36 per minute. The right pupil was 6 mm and 
sluggishly reactive to light; the left was 3 mm and reacted 
normally. There was complete palsy of all extraocular mus- 
cles. Right-sided rales were noted on examination of the 
chest, and heat-t examination showed normal findings. Hep- 
atosplenomegaly was present: the liver span was 17 cm and 
the spleen was papable 4 cm below the costal margin. The 
left testis was enlarged and indurated. Small ulcerated lesions 
from which herpes slmplex virus was cultured were observed 
on the buttocks. Mild generalized lymphadenopathy was 
noted. 
The white blood cell count was 12,800/mm3, the hemo- 
globin level 10.3 g/dl, and the platelet count 81,000/mm3. 
Abnormal chemical values included: serum glutamic oxalo- 
acetic transaminase 305 IWliter, serum glutamic pyruvic 
transaminase 165 IWliter, lactic dehydrogenase 3,7 10 IU/ 
liter, alkaline phosphatase 215 Ill/liter, uric acid 16 mg/dl, 
lactate 12.1 mg/dl, glucose 36 mg/dl, and creatine phos- 
phokinase 1,400 Ill/liter (100 percent mm fraction). The 
cerebrospinal fluid was xanthochromic and bloody. Bilateral 
pleural effusions were seen on chest radiography. Uttrasound 
of the abdpmen demonstrated hepatosplenomegaly with two 
solid masses within the liver. 
Results of tests for hepatitis B core and surface antibody 
were positive. Elevated titers to cytomegalovirus and Ep- 
stein-Barr virus were also noted (Table I). Immunologic 
studies revealed marked depression of lymphocyte prolif- 
eration in response to cytomegalovlrus antigen and con- 
canavalin A, elevated interferon levels, and an inverted T4:T8 
ratio (0.42; normal greater than 1.6). 
Burkitt’s lymphoblasts were seen in the peripheral blood 
(1 percent), pleural fluid, and spinal fluid. Lymph node and 
bone marrow biopsy specimens revealed Burl&t’s lymphoma. 
Tumor cells from several sources were Epstein-Barr virus 
nuclear antigen-positive, and DNA hybridization studies 
demonstrated 40 Epstein-Barr virus genome equivalents per 
cell (G. Miller, personal communication). Karyotyping re- 
vealed an 8;22 translocation [2]. 
On the third hospital day, 1,900 mg of cyclophosphamide 
(1,200 mg/m*) was administered intravenously. Fifty milli- 
grams of cytosine arabinoside (30 mg/m*) were given in- 
tfathecally on the second, third, fourth, and eighth hospital 
days. On the 12th hospital day, he received 12.5 mg of 
methotrexate intrathecally and a 42-hour infusion of high-dose 
methotrexate, followed by leucovorin rescue. 
There was dramatic improvement with resolution of the 
pleural effusion, lymphadenopathy, hepatosplenomegaly, 
testicular enlargement, and abnormal chemical values, and 
an improvement in eye movement. Burkitt’s cells were no 
longer seen in the spinal fluid. Repeated bone marrow biopsy 
revealed no lymphoma cells, and ultrasound showed reso- 
lution of the focal hepatic defects. 
Lumbar puncture was performed on the 29th hospital day 
for a further intrathecal injection of cytosine arabinoskte. On 
the following day, his temperature rose to 38.6OC but an in- 
fectious cause was not confirmed. On the 35th hospital day, 
the patient received intravenously 1,824 mg of cyclophos- 
phamide (1,200 mg/m*), 60 mg of doxorubicin hydrochloride 
(40 mg/m2), 2 mg of vincristine, and 60 mg of prednisone (40 
mg/m*). He was also given two of three scheduled daily 50 
mg doses of intrathecal cytosine arabinoside. After the first 
dose, nausea and vomiting developed, and after the second 
dose his temperature rose to 39.1°C. Results of multiple 
blood cultures remained negative. He complained of bilateral 
hip pain. Subsequently, there was decreasing responsive- 
ness, hypertension, bradycardia, and hypothermia. There was 
no papilledema, and the lower extremities were flaccid with 
loss of pinprick sensation. Opening pressure on lumbar 
puncture was 30 cm of water. Cerebrospinal fluid protein 
level was 1,160 mg/dl and white cell count 21/mmS, but no 
tumor cells were present. After the lumbar puncture, ob- 
tundation and hypoventilation developed. Mannitol and 
dexamethasone were given. Computed tomography revealed 
brain stem edema, marked enlargement of both lateral ven- 
tricles, and obliteration of the third and fourth ventricles. After 
ventriculostomy, the patient’s condition slowly improved. He 
was alert, able to squeeze with both hands, but unable to 
move his lower extremities despite painful stimuli. There was 
coarse horizontal nystagmus. Repeated scanning showed 
a marked decrease in the size of the ventricles. Six days after 
insertion, the shunt was removed and the patient became 
unresponsive. A major intracerebral hemorrhage was found 
by computed tomography, and he died on the following 
day. 
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Flgum 1. Vacuolar demyelination in 
do&al spinocerebellar tract of mid-cer- 
vical spin@ cord. Phagocytosed myelin 
can be seen in a macrophage (arrow- 
he8d) (Luxol fast blue and periodik acid- 
Schiff stain; originar magnification X 660, 
reduced by 30 percent). 
AuWpsy Flndings. Autopsy revealed necrotic lymphoma 
in marrow and pleura, and fibrosis in the testes. There was 
a large fresh hemorrhage in the tract of the ventricular shunt, 
with blood in all ventricles and subarachnoid space. 
Histologic examination showed noninflammatory, vacuolar 
demyelination of the white matter of the spinal cord (Figure 
l), brain stem, tuber cinereum, and cerebellum and myelin- 
ated axons of the cerebellar granular layer. The mildest 
changes consisted of multiple microvacuoles in myelin and 
axonal swellings (spheroids). Swelling of oligodendroglial 
cytoplasm was variably present, and multiple areas of 
demyelination with preferential loss of large diameter axons 
were also observed. Most of the damage was within white 
matter not more than 1 cm from$e subarachnoid space. 
In the spinal CoTd, vacuolar demyelination was bilateral and 
nearly symmetric. Myelin loss was most severe at depths of 
100 to 1,000 microns from the outer margin of white matter 
(Figure 2). A peripheral 50-to 2OO-micron rim of white matter 
in the region supplied by the arterial vasocorona was less 
affected. Damage overlapped adjacent tracts and was severe 
in the upper thoracic level. Medial portions of spinocerebellar 
tract and lateral portions of corticospjnal and spinothalamic, 
cuneate, gra@lis, and vestibulospinal tracts were involved. 
In the brain stem, vacuolar demyelination was most severe 
in the medulla where pyramids and olivocerebellar fibers 
were involved bilaterally. Corticospinal demyelination was 
present in the pons and cerebral peduncles. 
Cerebellar vacuolar demyelination of the white matter was 
multifocal and most extensive in the folia. The demyelination 
extended to the granular cell layer without affecting the 
number of granular cells. As in other affected regions, axonal 
swellings were conspicuous (Figure 3). 
There was no viable lymphoma, no lesions suggestive of 
toxoplasmosis, and organisms were not seen on special 
stains. rJ0 inflammation was present, viral inclusions were 
not found, and results of immunoperoxidase examinations 
for polyoma viruses were negative. Cerebrospinal fluid that 
had been stored during life was sent for myelin basic protein 
analysis. Results are shown in Figure 4. 
COMMENTS 
The findings in this patient were probably a conse- 
quence of unusually severe neurotoxicity associated 
with intrathecal chemotherapy occurring in a patient 
with suspected AIDS. Shortly after intrathecal cytosine 
arabinoside, nausea, vomiting, and fever developed, 
followed by bilateral hip pain and lethargy and then by 
signs of an intracranial herniation. There was evidence 
of paraplegia, which persisted until his death. It is not 
certain that this pitient’s neurologic complications were 
unequivocally due to the chemotherapy. However, the 
temporal relationship of onset of symptoms to the in- 
I --pm ~,.- -- ..“.--l 1 
Figure 2. Peripheral vacuolar demyelination in longikfdinal 
section of lower thoracio spinal cord (hematoxylin and eosin 
stain; winal msgnifcation X 11.5, re&zed by 30 percent). 
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trathecal cytosine arabinoside is suggestive, particularly 
in view of the findings on pathologic examination. The 
clinical picture differed in some respects from that 
previously reported in cases in which myelopathy was 
associated with intrathecal chemotherapy. As in other 
cases, the onset was acute; there was a suggestion of 
radicular pain with the hip pain, and there was both 
motor and sensory loss. Unlike other cases, the 
pathologic changes extended into the brain stem, 
causing edema, cerebrospinal fluid outflow obstruction, 
and a herniation syndrome. 
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Figure 4. Cerebrospinal fluid myelin basic protein (MBP) 
levels. Graph shows relationship to intrathecal (IT) chemo- 
therapy. The upper limit of normal is 5 @ml. Ara-C = cy- 
tosine arabinoside; MTX = methotrexate. 
Figure 3. Cerebellar folium. Axonal 
swellings are numerous in the secotuky 
lamina of white matter (upper hM). Axo- 
nal swellings are also present in the pri- 
mary lamina of white matter (large ar- 
rowhead) and in the granular cell layer 
(sfnall anowhead) (Bodian’s stain for 
axons; original magnification X 175, re- 
duced by 30 percent). 
Although the presence of AIDS in this patient cannot 
be proved, it was suspected in view of the usual clinical 
presentation for Burkitt’s lymphoma, with widespread 
disease, and the associated immunologic study results 
including impaired lymphocyte proliferation and a de- 
creased ratio of helper to suppressor T cells. Ziegler 
et al [l] recently described four homosexual males with 
a Burkitt’s-like lymphoma. These patients also had 
unusual presentations for Burkii’s lymphoma; three had 
central nervous system involvement. 
Neurologic disorders have been reported in 10 to 20 
percent of patients with AIDS. A large fraction of these 
patients have intracerebral mass lesions, frequently due 
to Toxoplasma gondii or npn-Hodgkin’s lymphoma [3]. 
In some lesions, biopsy or autopsy material has been 
nondiagnostic, showing a few viral inclusion bodies or 
nonspecific inflammatory reaction. 
Other prominent neurologic manifestations of AIDS 
include a progressive global dementia in v&i& cerebral 
biopsy specimens have shown nonspecific inflamma- 
tory changes and extensive demyelinization. Progres- 
sive multifocal leukoencephalopathy with cerebellar 
demyelination due to JC virus has also been reported 
[4]. Meningitis, particularly cryptococcal meningitis, 
has also been common, typically with subtle clinical 
presentations. Finally, a peripheral neuropathy of un- 
known origin has developed in many patients with AIDS. 
In the case presented, none of these possibilities could 
be shown to be responsible for the neurologic abnor- 
malities. 
Neurotoxicity associated with both cytosine arabin- 
oside and methotrexate has been described. Metho- 
trexate toxicity has included chemical arachnoiditis, 
paraparesis, and disseminated necrotizing leukoen- 
cephalopathy [ 5-81. Rarely, death has occurred im- 
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mediately after intrathecal injection of methotrexate [9]. 
Neurotoxicity with cytosine arabinoside has been de- 
scribed less frequently, but transient or permanent 
paraparesis and seizures have been observed [IO- 
121. 
Multiple case reports of paraparesis following in- 
trathecal cytosine arabinoside and methotrexate have 
appeared in the literature [5,7,9,10,12-221, with in- 
trathecal methotrexate most commonly involved. Fre- 
quently there was radicular pain. The onset of dys- 
function was usually immediate, and in most cases less 
than 40 hours. It was typically transient, but in some the 
neurologic deficits progressed or ascended over hours 
or days, with paraplegia and sensory levels as high as 
C7. In several cases, the deficit appeared perma- 
nent. 
There are few reported cases of neurotoxicity as- 
sociated with cytosine arabinoside alone. Wolff et al 
[ 121 described a 27-year-old patient with acute my- 
elogenous leukemia who received central nervous 
system prophylaxis with five 170 mg (100 mg/m*) doses 
of intrathecal cytosine arabinoside and cranial irradia- 
tion, followed in one month by lower extremity pares- 
thesias and weakness. Breuer et al [lo] reported a case 
of paraparesis following four 84 mg doses given for 
prophylaxis concurrent with cranial irradiation. Two 
weeks later, gait disturbance, lower extremity weak- 
ness, sensory loss, and urinary incontinence devel- 
oped. 
In none of these cases of paraplegia did herniation 
syndromes appear. However, Eden et al [ 1 l] reported 
the development of fever and generalized seizures after 
intrathecal cytosine arabinoside injection in two chil- 
dren. One of the children had signs of cerebral hernia- 
tion that responded to dexamethasone and mannitol. 
Various suggestions have been made concerning the 
pathogenesis of cytosine arabinoside or methotrexate 
neurotoxicity, but none of them has been proved 
[7,10,15,18,23]. Only a few of the patients have un- 
dergone post mortem examination, which has revealed 
demyelination of the cord. Simple removal and rein- 
jection of 1 cc aliquots of cerebrospinal fluid has been 
noted to cause demyelination with posterior extremity 
paralysis in cats [24]. 
The syndrome of myelopathy following intrathecal 
chemotherapy is distinct from that of necrotizing leu- 
koencephalopathy associated with systemic or intra- 
thecal methotrexate and cranial irradiation [8,8,23,25]. 
The latter syndrome is characterized by demyelination 
in the brain tissue plus multifocal necrosis, astrocytosis, 
and occasionally dystrophic calcification. Levels of 
myelin basic protein, which is specific to the myelin 
sheath, are elevated in the cerebrospinal fluid [21], as 
in multiple sclerosis, in which levels of myelin basic 
protein correlate with the degree of active demyelina- 
tion [26,27]. 
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With few exceptions, cerebrospinal fluid myelin basic 
protein levels have not been recorded in patients with 
myelopathy due to intrathecal chemotherapy. Gangji et 
al [21] noted a transiently elevated level in a patient 
with acute-onset, right-sided hemiparesis after pro- 
phylactic intrathecal methotrexate and cranial irradia- 
tion. Clark et al [ 221 described a patient who had had 
numerous courses of intrathecal methotrexate and 
cytosine arabinoside for central nervous system leu- 
kemia of long duration, and in whom sensory loss and 
paraplegia developed accompanied by a myelin basic 
protein level of 17 rig/ml four weeks after bone marrow 
transplantation. A fatal ascending myelopathy char- 
acterized by a myelin basic protein level greater than 
40 rig/ml developed in a patient at the National Cancer 
Institute after extensive treatment for central nervous 
system leukemia [28]. In the patient described herein, 
the myelin basic protein level was weakly positive (6.0 
rig/ml) after four intrathecal injections of cytosine ar- 
abinoside. After the level normalized during a period 
free from drug administration, more intrathecal cytosine 
arabinoside was given and the level rose to 19 rig/ml 
coincident with neurologic deterioration. 
Microscopic findings in the present case were very 
similar to findings in the cases reported by Breuer et al 
[lo] and Clark et al [22]. Major features in common 
were vacuolar myelin loss with axonal swellings but 
without necrosis or inflammation and with localization 
of the damage to myelin near the cerebrospinal fluid of 
the subarachnoid space. However, in the present case, 
destruction was not confined to the spinal cord. Vacu- 
olar demyelination, microscopically identical to that 
seen in the spinal cord, affected multiple regions of 
brain stem and cerebellum. These regions had not been 
irradiated and were devoid of necrosis and calcification 
described in association with necrotizing leukoence- 
phalopathy [6,8,23,25]. Thus, the myelopathy was 
more severe clinically and pathologically than any 
previously reported. 
In summary, widespread Burkitt’s lymphoma devel- 
oped in a 30-year-old homosexual man with suspected 
AIDS. He had a complete clinical response to the first 
dose of cyclophosphamide but then had neurologic 
deterioration temporally related to intrathecal chemo- 
therapy with cytosine arabinoside. Clinically, the initial 
manifestations were fever, nausea, vomiting, and bi- 
lateral hip pain. Following recovery from increased 
intracranial pressure due to brain stem edema, there 
was persistent paraplegia. On postmortem examination, 
extensive demyelination involving the cord and brain 
stem was seen, but without necrosis. Although it ap- 
peared to be a complication of intrathecal chemother- 
apy, a syndrome this extensive has not been previously 
described. Whether the suspected underlying AIDS may 
have been related to the development or severity of the 
demyelination syndrome is speculative. 
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